Merck is no longer in discussions to buy biotech Revolution Medicines, according to people familiar with the matter. Merck had recently been in talks to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion. The talks cooled after the two couldn’t come to an agreement on price, some of the people said. It is always possible talks could restart or another suitor for RevMed could emerge. The Journal reported earlier this month that AbbVie was in advanced talks for a deal for Revolution, which was drawing interest from multiple suitors. AbbVie later said it “is not in discussions” with Revolution.
Read the full article: Merck No Longer in Talks to Buy Revolution Medicines //
Source: https://www.msn.com/en-us/health/other/merck-no-longer-in-talks-to-buy-revolution-medicines/ar-AA1UWGIK